LITESPARK-011Phase 3 Belzutifan plus lenvatinib vs. cabozantinib monotherapy in patients with ccRCC with prior anti-PD-1/PD-L1 therapy. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.